Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides

Abstract

During last decades multiple therapeutic approaches have been explored for improved management of peritoneally disseminated malignancies – a grim condition known as peritoneal carcinomatosis (PC). Intraperitoneal administration can be used to achieve elevated local concentration and extended half-life of the drugs in the peritoneal cavity to improve their anticancer efficacy. However, IP-administered chemotherapeutics have a short residence time in the IP space, and are not tumor selective. An increasing body of work suggests that functionalization of drugs and nanoparticles with targeting peptides increases their peritoneal retention and provides a robust and specific tumor binding and penetration that translates into improved therapeutic response. Here we review a progress in affinity targeting of intraperitoneal anticancer compounds, imaging agents and nanoparticles with tumor homing peptides. We review classes of tumor homing peptides relevant for PC targeting, payloads for peptide-guided precision delivery, applications for targeted compounds and the effects of nanoformulation of drugs and imaging agents on affinity-based tumor delivery.

The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy

“…The only radiocompounds described in the literature, related to the first group, are based on ATWLPPR (A7R) peptidomimetic used alone or conjugated with RGD peptide. A7R is known as in vivo anti-angiogenic and anti-tumour agent [ 35 , 36 , 276 ].…”

“…Additionally, neuropilin 1 (NRP-1) a major co-receptor of VEGFR-2, as well as an independent receptor, is involved in the regulation of physiological and pathological angiogenic processes. For this reason, current research has focused on various neuropilin-targeting substances due to its possible application of anticancer therapy [ 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 ].…”

Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma

“…TPPs are widely used as tumor-homing affinity ligands in targeted therapies, as they combine tumor specificity with cargo to reduce toxicity and increase efficacy [ 17 , 20 , 21 , 22 , 23 , 24 , 25 ]. In previous work, we paired TPPs with an Interfering Peptide (IP) that blocks the interaction between the phosphatase PP2A and its physiological inhibitor, the oncoprotein SET.…”